Cormorant Asset Management, LP holds a focused book of 46 stocks worth $2.0B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Erasca Inc and trimmed Praxis Precision Medicines I. Their largest long position is Praxis Precision Medicines I at 14% of the equity book. They also disclosed $7.5M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1583977/holdings"
Use Arkolith to show Cormorant Asset Management, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I COM NEW | $285.3M | 885.5K | 14.4% | ▼−6.8% Reduced · −65K sh | |
| 2 | Bridgebio Oncology Therapeut COM NEW | $160.0M | 17.88M | 8.1% | —Held | |
| 3 | Eyepoint Inc COM NEW | $106.5M | 8.27M | 5.4% | —Held | |
| 4 | Edgewise Therapeutics Inc COM | $102.7M | 3.26M | 5.2% | ▼−0.8% Reduced · −25K sh | |
| 5 | Erasca Inc COM | $93.8M | 5.80M | 4.7% | ▲New New position | |
| 6 | Rapport Therapeutics Inc COM | $92.5M | 2.96M | 4.7% | ▼−2.3% Reduced · −70K sh | |
| 7 | Alumis Inc COM | $87.0M | 3.95M | 4.4% | ▲+8.6% Added · +314K sh | |
| 8 | Abivax Sa SPONSORED ADS | $84.6M | 760.0K | 4.3% | ▼−44% Reduced · −590K sh | |
| 9 | Moonlake Immunotherapeutics CLASS A ORD | $83.5M | 4.48M | 4.2% | ▲+2.9% Added · +125K sh | |
| 10 | Dianthus Therapeutics Inc COM | $79.7M | 950.0K | 4.0% | ▲New New position | |
| 11 | Bright Minds Biosciences Inc COM NEW | $77.3M | 1.06M | 3.9% | —Held | |
| 12 | Bridgebio Pharma Inc COM | $63.1M | 850.0K | 3.2% | ▼−29% Reduced · −350K sh | |
| 13 | Olema Pharmaceuticals Inc COM | $58.1M | 3.90M | 2.9% | ▲+42% Added · +1.1M sh | |
| 14 | Bioage Labs Inc COM | $50.6M | 2.89M | 2.5% | ▲+42% Added · +850K sh | |
| 15 | Centessa Pharmaceuticals PLC SPONSORED ADS | $41.7M | 1.05M | 2.1% | ▼−21% Reduced · −275K sh | |
| 16 | Damora Therapeutics Inc COM NEW | $39.5M | 1.52M | 2.0% | ▲New New position | |
| 17 | MBX Biosciences Inc COM | $33.4M | 1.12M | 1.7% | —Held | |
| 18 | Insmed Inc COM PAR $.01 | $31.1M | 190.0K | 1.6% | ▼−31% Reduced · −85K sh | |
| 19 | Newamsterdam Pharma Company ORDINARY SHARES | $30.4M | 950.0K | 1.5% | ▼−5.0% Reduced · −50K sh | |
| 20 | Tango Therapeutics Inc COM | $29.8M | 1.43M | 1.5% | ▲New New position | |
| 21 | Pharvaris N V COM | $28.3M | 1.00M | 1.4% | ▼−7.7% Reduced · −83K sh | |
| 22 | Oruka Therapeutics Inc COM | $26.2M | 533.3K | 1.3% | —Held | |
| 23 | Agomab Therapeutics NV SPONSORED ADS | $25.9M | 2.47M | 1.3% | ▲New New position | |
| 24 | Maze Therapeutics Inc COM | $22.4M | 750.0K | 1.1% | ▲New New position | |
| 25 | Corbus Pharmaceuticals Hldgs COM NEW | $22.0M | 2.34M | 1.1% | —Held | |
| 26 | Ascendis Pharma A/s SPONSORED ADR | $21.7M | 95.0K | 1.1% | ▼−5.0% Reduced · −5K sh | |
| 27 | Roivant Sciences Ltd SHS | $20.8M | 750.0K | 1.0% | ▲New New position | |
| 28 | Adlai Nortye Ltd SPONSORED ADS | $20.1M | 2.90M | 1.0% | ▲New New position | |
| 29 | Terns Pharmaceuticals Inc COM | $15.8M | 300.0K | 0.8% | ▲New New position | |
| 30 | Tarsus Pharmaceuticals Inc COM | $15.8M | 225.0K | 0.8% | ▼−10% Reduced · −25K sh | |
| 31 | Biohaven Ltd COM | $14.9M | 1.76M | 0.8% | ▲176× Added · +1.8M sh | |
| 32 | Cabaletta Bio Inc COM | $14.8M | 5.50M | 0.7% | ▲+25% Added · +1.1M sh | |
| 33 | Helix Acquisition Corp III USD CL A ORD SHS | $13.2M | 1.30M | 0.7% | ▲New New position | |
| 34 | Arcutis Biotherapeutics Inc COM | $10.6M | 450.0K | 0.5% | ▼−10% Reduced · −50K sh | |
| 35 | Sensei Biotherapeutics Inc COM NEW | $9.7M | 306.2K | 0.5% | ▲New New position | |
| 36 | Crinetics Pharmaceuticals In COM | $9.1M | 250.0K | 0.5% | ▼−17% Reduced · −50K sh | |
| 37 | Zura Bio Ltd CLASS A ORD SHS | $8.6M | 1.45M | 0.4% | ▲New New position | |
| 38 | Axsome Therapeutics Inc. COM | $8.5M | 50.0K | 0.4% | ▼−33% Reduced · −25K sh | |
| 39 | Structure Therapeutics Inc SPONSORED ADS | $8.4M | 175.0K | 0.4% | ▲New New position | |
| 40 | Cogent Biosciences Inc COM | $7.7M | 200.0K | 0.4% | ▼−11% Reduced · −25K sh | |
| 41 | Monte Rosa Therapeutics Inc COM | $6.6M | 400.0K | 0.3% | ▲New New position | |
| 42 | Arrowhead Pharmaceuticals In COM | $6.3M | 100.0K | 0.3% | ▲New New position | |
| 43 | Vaxcyte Inc COM | $5.8M | 100.0K | 0.3% | ▼−20% Reduced · −25K sh | |
| 44 | Amylyx Pharmaceuticals Inc COM | $4.9M | 350.0K | 0.2% | ▼−13% Reduced · −50K sh | |
| 45 | Rallybio Corp COM | $3.6M | 400.0K | 0.2% | ▲New New position | |
| 46 | Context Therapeutics Inc COM | $1.4M | 529.5K | 0.1% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | OLEMA PHARMACEUTICALS INCOLMA | $7.5M | 500K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 47 | $2.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 35 | $2.2B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 36 | $1.4B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 42 | $1.3B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 44 | $1.3B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 48 | $1.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45 | $1.9B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 49 | $1.7B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 57 | $2.3B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 48 | $2.1B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 49 | $1.7B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 64 | $1.8B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 72 | $1.5B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 73 | $1.5B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 73 | $1.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 80 | $1.3B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 77 | $1.3B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 78 | $1.7B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 88 | $2.5B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 104 | $2.9B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 120 | $4.5B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 105 | $4.2B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 93 | $2.6B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 81 | $2.6B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.